U.S. Markets open in 6 hrs 19 mins
  • S&P Futures

    3,362.50
    -20.50 (-0.61%)
     
  • Dow Futures

    27,183.00
    -182.00 (-0.67%)
     
  • Nasdaq Futures

    11,537.75
    -50.25 (-0.43%)
     
  • Russell 2000 Futures

    1,572.70
    -16.30 (-1.03%)
     
  • Crude Oil

    38.56
    -1.01 (-2.55%)
     
  • Gold

    1,908.10
    -3.80 (-0.20%)
     
  • Silver

    24.57
    0.00 (0.00%)
     
  • EUR/USD

    1.1777
    -0.0012 (-0.1060%)
     
  • 10-Yr Bond

    0.7780
    0.0000 (0.00%)
     
  • Vix

    33.35
    +0.89 (+2.74%)
     
  • GBP/USD

    1.3055
    +0.0014 (+0.1070%)
     
  • USD/JPY

    104.1880
    -0.3060 (-0.2928%)
     
  • BTC-USD

    13,699.34
    -51.30 (-0.37%)
     
  • CMC Crypto 200

    270.85
    +9.56 (+3.66%)
     
  • FTSE 100

    5,728.99
    -63.02 (-1.09%)
     
  • Nikkei 225

    23,418.51
    -75.79 (-0.32%)
     

Akebia Therapeutics to Report Fourth Quarter and Full-Year 2019 Financial Results and Discuss Recent Business Highlights

·1 min read

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people with kidney disease, today announced plans to release its fourth quarter and full-year 2019 financial results, on Tuesday, March 10, 2020 before the opening of the financial markets.

Akebia will host a conference call at 9:00 a.m. Eastern Time on Tuesday, March 10th, to discuss its fourth quarter and full-year 2019 financial results and recent business highlights. To listen to the conference call, please dial (877) 458-0977 (domestic) or (484) 653-6724 (international) using conference ID number 6572299. The call will also be webcast LIVE and can be accessed via the Investors section of the Company’s website at http://ir.akebia.com.

A replay of the conference call will be available two hours after the completion of the call through March 16, 2020. To access the replay, dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and reference conference ID number 6572299. An online archive of the conference call can be accessed via the Investors section of the Company’s website at http://ir.akebia.com.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200224005093/en/

Contacts

Kristen K. Sheppard, Esq
ir@akebia.com